Phase 3 peer review result of Sinopharm Beijing and Wuhan vaccines. The Journal of American Medical Association.
The incidence rate (per 1000 person-years) was 12.1 (95% CI, 8.3-17.8) in the WIV04 group, 9.8 (95% CI, 6.4-15.0) in the HB02 group, and 44.7 (95% CI, 36.6-54.6) in the alum-only group. This resulted in a vaccine efficacy, compared with the alum-only group, of 72.8% ([95% CI 58.1%-82.4%];
P < .001) for the WIV04 group and 78.1% ([95% CI, 64.8%-86.3%];
P < .001) for the HB02 group
A total of 47 asymptomatic cases of COVID-19 were identified 14 days following the second dose: 16 in the WIV04 group, 10 in the HB02 group, and 21 in the alum-only group. Thus, the total number of cases of COVID-19 (including both symptomatic and asymptomatic cases) was 42 in the WIV04 group, 31 in the HB02 group, and 116 in the alum-only group. A post hoc analysis adding the asymptomatic cases resulted in a vaccine efficacy of 64.0% (95% CI, 48.8%-74.7%) for the WIV04 vaccine and 73.5% (95% CI 60.6%-82.2%) for the HB02 vaccine
Thus, the total number of cases after the first dose was 69 in the WIV04 group, 48 in the HB02 group, and 138 in the alum-only group. A post hoc analysis that additionally included those cases resulted in a vaccine efficacy of 50.3% (95% CI 33.6%-62.7%) for the WIV04 vaccine and 65.5% (95% CI 52.0%-75.1%) for the HB02 vaccine against symptomatic cases of COVID-19 after the first dose.